Nanobiotix S.A.

NASDAQ:NBTX

Biotechnology

Healthcare
$27.32 -0.91%

-$0.33 today

Market cap
$1.39B
Beta
0.59
P/E (TTM)
-60.2
EPS (TTM)
-$0.51
52W Low $4.31High $57.14

Volume 0.18M

Average 0.08M

Returns on capital

Nanobiotix S.A. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

28.4%

avg 403.0%

ROIC

-74.3%

avg -122.8%

ROA

-35.4%

avg -62.1%

Analysis

ROE is currently the strongest return metric at 28.4% versus its period average of 403.0%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Laurent Levy

Co-Founder, President of the Executive Board & Chief Executive OfficerEUR 949.24K53——

Louis Kayitalire

Chief Medical Officer & Member of Executive BoardEUR 677.64K67——

Bart Van Rhijn

Chief Financial & Business Officer and Member of Executive BoardEUR 675.62K52——

Anne-Juliette Hermant

Chief People Officer & Member of Executive BoardEUR 465.59K52——

Leonard A. Farber

Chief Clinical and Medical Affairs Officer & Chairman of the Scientific Advisory Board————

Arnd Christ

CFO & Member of Executive Board—60——

Margaret Galluzzi

Vice President & Global Head of Clinical Operations————

Brandon Owens

Vice President of Strategic Marketing & Corporate Communication————

Earl J. Bergey

Co-Founder—71——

Anne-Sophie Lariviere

Chief Product Innovation & Delivery Officer————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

No open-market purchases or sales in the last 12 months.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/A+83.8%
+37.6% (5yr)2 analysts
Net IncomeN/AN/AN/A
N/A2 analysts
EBITN/AN/AN/A
N/A2 analysts

Analysis

Recent growth has been strongest in Revenue at +83.8% over three years. Forward estimates point to Revenue at +37.6% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Nanobiotix S.A. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about NBTX's management, answered from reported figures.

Who manages NBTX?

Nanobiotix S.A. (NBTX) lists 10 active executives. The top listed executive is Laurent Levy, Co-Founder, President of the Executive Board & Chief Executive Officer.